Abstract Protein arginine methyltransferase 1 (PRMT1) serves as a crucial regulator of post-translational modifications of proteins. While PRMT1 has been implicated in the progression of various cancers, its specific role in chronic lymphocytic leukemia (CLL) remains to be fully elucidated. This study aimed to investigate the oncogenic function of PRMT1 and assess the therapeutic efficacy of a selective PRMT1 inhibitor, C7280948, in CLL.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile